gsk1292263
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00783549)
Timeline
Indications
Mechanism of action
GPR119 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- (1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methyl methanesulfonate
- gsk1292263
- gsk1292263
- gsk1292263
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01218204 | Phase 2 | Sep 1, 2010 | GlaxoSmithKline |
| NCT01101568 | Phase 1 | Apr 14, 2010 | GlaxoSmithKline |
| NCT01128621 | Phase 2 | Nov 1, 2009 | GlaxoSmithKline |
| NCT01119846 | Phase 2 | Jun 1, 2009 | GlaxoSmithKline |
| NCT00783549 | Phase 1 | Sep 1, 2008 | GlaxoSmithKline |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 5 | 5 | 2 | 2008 |
1 organizations
Page 1 / 1